Biotech Values

[MotionMan]

MNTA: As a mnta shareholder, I'd rather see MNTA independent. I can't see NVS offering anything close to full value yet. Too many question marks.
The potential is immense if 3 years from now MNTA retains sole generic status of Lovenox and Copaxone. Could equal 800 to 900 million in yearly revenue.
If NVS offers 3.5 to 4 billion then I listen. Call me greedy. But even though the engine is running, MNTA hasn't even gotten off the ground yet.